hepatitis C – media

Fatty Liver Recovers Speedily After Hepatitis C Cure

A report in Alimentary Pharmacology and Therapeutics revealed that Liver stiffness and liver fat (steatosis) in chronic hepatitis C virus (HCV) infected patients improved considerably post-treatment with direct-acting antivirals (DAAs) resulting in sustained virological response (SVR). A fall in ALT levels and a rise in platelet count was observed six months after SVR.
- Source: WorldHepatitisAlliance
- 1,322
- July 24, 2018
Fatty liver disease hepatitis C Researches
HCV RNA PCR Test; Qualitative and Quantitative Analysis

The HCV RNA PCR test is a blood test that is advised by doctors in suspected patients to diagnose Hepatitis C infection. It calculates the hepatitis C viral load in the bloodstream. This article gives an insight into how the test functions and what the results signify.
- Source: MedicalNewsToday
- 1,393
- July 20, 2018
blood test hepatitis C Researches
What You Need to Know about Hepatitis C

Hepatitis C is a chronic, potentially fatal disease affecting the liver and is caused by a viral infection most frequently transmitted through large or repeated direct percutaneous exposures to infected blood. The two most common exposures associated with transmission of HCV are blood transfusion and injection drug use. It proves to be deadly because it develops silently i.e. it does not produce any marked signs and symptoms until it has progressed to an advanced stage.
- Source: Help4Hep
- 706
- July 12, 2018
health hepatitis C Researches
US Prison Inmates with Hepatitis C Devoid of Treatment

Reports reveal that as many as 144,000 inmates of state prisons in the United States who have hepatitis C are not being given any kind of treatment. Corrections departments in every state were enquired about the number of inmates with hepatitis C, the treatment they were receiving, the drugs used for their treatment and also about policies that exist which concern inmates inflicted with the virus.
- Source: Speciality Pharmacy Times
- 649
- July 11, 2018
hepatitis C Policies
HCV Patients can Donate Kidneys

A research team led by the University of Cincinnati revealed that patients in need of kidney can opt for transplantation by safely receiving a kidney from an HCV-infected donor. This report was published online in Annals of Internal Medicine.
- Source: MedPageToday
- 669
- July 11, 2018
hepatitis C kidney Researches
Hep C Antibody Test

The hepatitis C antibody test detects antibodies for the hepatitis C virus in the blood. Antibodies in the body indicate that a person has been infected with the virus at some point. However, it does not always mean that they still have the virus.
- Source: Medical News Today
- 930
- July 10, 2018
health tips hepatitis C Researches
DHA Announces Free Hepatitis C Screening & Treatment in Dubai

Hepatitis C is caused by the Hepatitis C virus (HCV), which affects the liver. The World Health Organization (WHO) reported that around 399,000 people die every year due to Hepatitis C throughout the world. Hepatitis C leads to cirrhosis and liver cancer since it is diagnosed only at a late stage.
- Source: GulfNews
- 775
- July 10, 2018
hepatitis C Market Views Policies UAE
Cost Effective Universal Screening Aids in Eliminating Hepatitis C

In response to the issue, the scientific team of Professor Yazdan Yazdanpanah's Inserm and Sylvie Deuffic-Burban created a mathematical model to estimate the efficiency and cost-effectiveness of varied screening strategies which includes universal screening.
- Source: News Medical
- 806
- July 6, 2018
blood test hepatitis C Policies
WHO Reports Improvement in Hepatitis-C Cure Annually

A report was issued by the World Health Organization (WHO) recently that the number of people receiving hepatitis C cures was increased from 1 million in 2015 to 1.5 million in 2016. Previously, only a small number of countries took part in hepatitis C treatments.
- Source: WHO
- 952
- July 5, 2018
hepatitis C Market Views WHO
Drugs for Neglected Diseases initiative and Pharco Pharmaceuticals to test affordable hepatitis C regimen with support of Malaysian and Thai governments

Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300
- Source: dndi
- 662
- April 17, 2018
Clinical Trials hepatitis C

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.